Tsewang Tashi, MD
Languages spoken: English, French, Hindi, Mandarin Chinese, Urdu, Tibetan
Academic Information
Departments: Internal Medicine - Assistant Professor (Clinical)
Divisions: Hematology/BMT
Academic Office Information
(801) 581-5062
Board Certification
- American Board of Internal Medicine (Internal Medicine)
- American Board of Internal Medicine (Sub: Hematology)
- American Board of Internal Medicine (Sub: Medical Oncology)
Research Interests
- Myeloid Malignancies
- Hypoxia
Dr. Tsewang Tashi joined the University of Utah faculty after completing his hematology/oncology fellowship in 2015, and is involved in research with Dr. Josef Prchal on high altitude genetic adaptation, hypoxia signaling and molecular genetics of myeloproliferative neoplasms. He received his medical degree from Chang Gung University, Taiwan, and completed his internal medicine residency both in Taiwan, and in the US from Creighton University Medical Center, Omaha, NE. His research and clinical interest lies in myeloid malignancies and currently sees patients with myeloproliferative neoplasms, including systemic mastocytosis. He established and currently leads the Mastocytosis Program at the Huntsman Cancer Hospital. Additionally, he also sees patients at the University of Utah's South Jordan Huntsman clinic and also serves veterans at the Salt Lake City VA Medical Center.
Education History
| Graduate Training |
University of Utah Master of Science in Clinical Investigation |
M.S.C.I |
|---|---|---|
| Fellowship |
University of Utah Hematology/Oncology |
Fellow |
| Residency |
Creighton University Internal Medicine |
Resident |
| Residency |
Pingtung Christian Hospital Internal Medicine |
Resident |
| Internship |
MacKay Memorial Hospital Internal Medicine |
Intern |
| Professional Medical |
Chang Gung University School of Medicine Medicine |
M.D. |
Selected Publications
- Tashi T, Yu J, Pandya S, Dieyi C, Scherber R, Parasuraman S (2023). Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 23(1), 48.
- Chuah YY, Tashi T, Kuo CJ (2022). An unexpected cause of Cullen's sign: rupture of hepatocellular carcinoma. Br J Hosp Med (Lond), 83(11), 1.
- Verstovsek S, Mesa R, Mascarenhas J, Tashi T, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C (2022). MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S342-S343.
- Tashi T (2022). Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera. [Review]. Fed Pract, 39(Suppl 2), S43-S46.
- Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237.
- Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130.
- Chuah YY, Tashi T, Lee YY, Fu TY, Shih CA (2020). Enteropathy-associated T-cell Lymphoma (EATL) with intracranial metastasis : a rare and dismal condition. Acta Gastroenterol Belg, 83(1), 77-80.
- Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121.
Global Impact
Education History
| Type | School | Degree |
|---|---|---|
| Internship | MacKay Memorial Hospital Internal Medicine |
Intern |
| Professional Medical | Chang Gung University School of Medicine Medicine |
M.D. |
| Residency | Pingtung Christian Hospital Internal Medicine |
Resident |